Biomm S.A
Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a Human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; and Lifepen G, a reusable insulin injection pen. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-st… Read more
Biomm S.A - Asset Resilience Ratio
Biomm S.A (BIOM3) has an Asset Resilience Ratio of 14.65% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Biomm S.A's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Biomm S.A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | R$11.50 Million | 2.37% |
| Short-term Investments | R$59.53 Million | 12.27% |
| Total Liquid Assets | R$71.03 Million | 14.65% |
Asset Resilience Insights
- Moderate Liquidity: Biomm S.A has 14.65% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Biomm S.A Industry Peers by Asset Resilience Ratio
Compare Biomm S.A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Biomm S.A (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Biomm S.A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 29.70% | R$138.28 Million | R$465.66 Million | +14.47pp |
| 2023-12-31 | 15.22% | R$52.47 Million | R$344.70 Million | -9.16pp |
| 2022-12-31 | 24.38% | R$98.78 Million | R$405.09 Million | +9.69pp |
| 2021-12-31 | 14.69% | R$54.34 Million | R$369.83 Million | -10.23pp |
| 2020-12-31 | 24.93% | R$108.43 Million | R$434.97 Million | -1.88pp |
| 2019-12-31 | 26.80% | R$104.21 Million | R$388.77 Million | +2.25pp |
| 2018-12-31 | 24.55% | R$75.06 Million | R$305.68 Million | +11.50pp |
| 2017-12-31 | 13.06% | R$34.26 Million | R$262.39 Million | -3.19pp |
| 2016-12-31 | 16.25% | R$38.57 Million | R$237.38 Million | -22.95pp |
| 2015-12-31 | 39.20% | R$90.03 Million | R$229.67 Million | -17.51pp |
| 2014-12-31 | 56.71% | R$101.83 Million | R$179.56 Million | +4.71pp |
| 2013-12-31 | 52.00% | R$71.80 Million | R$138.08 Million | -- |